\u2018Mood disorders\u2019 is encompass a range of different conditions, including:<\/p>\n
Bipolar disorder is characterised by manic and depressive episodes that are separated by periods of low mood. Those diagnosed with a mood disorder may experience difficultly sleeping and changes in appetite and or\/concentration. Mood disorders are very common.<\/p>\n
At Oxford Health, researchers are interested in learning more about the causes of mood disorders, with the aim of developing better treatments. Researchers are also interested in learning more about how we may be able to prevent mood disorders through early identification.<\/p>\n
ALTO-100-211<\/strong><\/p>\n Principal Investigator: Emily McGregor – Clinical Research Nurse<\/p>\n Objective<\/strong>: Compare the antidepressant efficacy of ALTO-100 versus placebo in adults with bipolar disorder with depression who are already taking mood stabilisers and\/0r permitted atypical antipsychotics.<\/p>\n <\/p>\n ANTLER 75+<\/strong><\/p>\n Principal Investigator: Dr Philip Wilkinson – Consultant Psychiatrist<\/p>\n Objective<\/strong>: To evaluate the effectiveness of continuing antidepressants for the treatment of depression in the over 75 age group.<\/p>\n <\/p>\n ASCEND<\/strong><\/p>\n Principal Investigator: Professor Cipriani-Director of the Clinical Research Facility and Eodardo Ostinell- Consultant Psychiatrist<\/p>\n Objective<\/strong>: We want to find out if using a sertraline\/aripiprazole combination will be beneficial in reducing depressive symptoms in people with bipolar.<\/p>\n <\/p>\n CONTACT-GAD<\/strong><\/p>\n Principal Investigator: Dr Phillip Wilkinson- Consultant Psychiatrist<\/p>\n Objective<\/strong>: Aiming to understand if a new form of ACT therapy for older people with treatment resistant Generalised Anxiety Disorder combined with treatment as usual, is effective in reducing anxiety compared to usual care alone.<\/p>\n <\/p>\n DPIM<\/strong><\/p>\n Principal Investigator: Dr Digby Quested- Consultant Psychiatrist<\/p>\n Objective<\/strong>: To find genetic or other cause of mental illness by studying DNA in the blood or saliva .<\/p>\n <\/p>\n GLAD<\/strong><\/p>\n Principal Investigator: Francesca Waddington- Senior Clinical Research Assistant<\/p>\n Objective:<\/strong> The GLAD study is investigating genetic factors of anxiety and depression. All participants will be invited to join the NIHR Mental Health BioResource which will in future offer participants further relevant research opportunities.<\/p>\n <\/p>\n GlobalMinds<\/strong><\/p>\n Principal Investigator: Dr Philip McGuire – Consultant Psychiatrist<\/p>\n Objective:\u00a0<\/strong>To develop an internationally diverse bioresource linking genetic and healthcare information in individuals with schizophrenia, psychosis, depression or bipolar.<\/p>\n <\/p>\n MAPS- MENSTRUAL CYCLE AND PSYCHOTIC SYMPTOMS<\/strong><\/p>\n Principal Investigator: <\/strong>Dr Thomas Reilly<\/p>\n Objective: <\/strong>This study aims to measure how mental health symptoms changes across the menstrual cycle.<\/p>\n <\/p>\n moreRESPECT<\/strong><\/p>\n Principal Investigator: <\/strong>Abiola Jokomba – Ward Manager<\/p>\n Objective: <\/strong>To understand if a tailored sexual health intervention able to reduce unprotected sexual acts and increase knowledge about sexually transmitted diseases and healthy relationships.<\/p>\n <\/p>\n Renew-MDD-1<\/strong><\/p>\n Principal Investigator: <\/strong>Dr Riccardo Di Giorgi – Clinical Lecturer and Consultant Psychiatrist<\/p>\n Objective: <\/strong>To evaluate if the novel drug brenipatide, a GLP receptor agonist, delays time to relapse compared to placebo for patients with Major Depressive Disorder in or near remission. Brenipatide will be taken alongside current standard and stable antidepressant therapy.<\/p>\n <\/p>\n TARIAN-1<\/strong><\/p>\n Principal Investigator: <\/strong>Professor Michael Browning – Professor of Computational Psychiatry<\/p>\n Objective: <\/strong>To evaluate if a novel antidepressant DT-101 reduces depressive symptoms in patients with Major Depressive Disorder.<\/p>\n <\/p>\n Tri-Prep<\/strong><\/p>\n Principal Investigator: <\/strong>Dr Andrew Molodynski – Consultant Psychiatrist<\/p>\n Objective: <\/strong>investigate the views, understandings and perspectives of people with severe mental illness and mental health professionals on smoking\/vaping, reduction and cessation. This study will inform the design of future research on helping people with severe mental illness to reduce smoking, finding out how we can make our research acceptable and suitable for participants.<\/p>\n<\/div>\n <\/details>\n We have a verity of different studies.\u00a0 Some involve a questionnaires, some involve a therapy and some involve taking a medication.\u00a0 Some\u00a0 take place in our research clinics, in a clinical team base or sometimes they can take place in your home.<\/p>\n \u00a0We are sometimes able to contact people directly about research, or get referrals from clinical teams. We are always appreciate hearing from people who are interested in getting involved.<\/span><\/p>\n There are many opportunities to become involved in research at Oxford Health if you experience a mood disorder. If you are interested in taking part, please contact us on: mentalhealthresearch@oxfordhealth.nhs.uk<\/a> for further information on our current research opportunities.<\/p>\n You can find more information on previous research studies here<\/a>.<\/p>\nKey contacts<\/h2>\n
Previous research studies<\/h2>\n
Research Clinics<\/h2>\n